Atlas FDA

BAROSTIM NEO® System

FDA premarket approval P180050 · decided 2019-08-16

Approval details

PMA number
P180050
Trade name
BAROSTIM NEO® System
Generic name
Stimulator, carotid sinus nerve
Applicant
Cvrx, Inc.
Date received
2018-12-20
Decision date
2019-08-16
Days to decision
239 days
Decision code
APPR
Product code
DSR
Advisory committee
Cardiovascular
Expedited review
No
Location
Minneapolis, MN
Statement
Approval for The BAROSTIM NEO System. The device is indicated for the improvement of symptoms of heart failure. quality of life, six-minute hall walk and functional status, for patients who remain symptomatic despite treatment with guideline-directed medical therapy, are NYHA Class III or Class II (who had a recent history of Class III), have a left ventricular ejection fraction <= 35%, a NT-proBNP < 1600 pg/ml and excluding patients indicated for Cardiac Resynchronization Therapy (CRT) accordin

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.